Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Shebli Atrash"'
Autor:
Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castaneda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B. Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/3e7b6b54104143d6819770a8ea596373
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Although multiple myeloma is an incurable disease, the past decade has witnessed significant improvement in patient outcomes. This was brought about by the development of T-cell redirection therapies such as chimeric antigen receptor (CAR) T-cells, w
Externí odkaz:
https://doaj.org/article/cb01826a48704e59aa792602432d229d
Autor:
Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed cl
Externí odkaz:
https://doaj.org/article/ba30b147cb5a40229e9257f0ed0c5838
Autor:
Hamid Ehsan, Myra Robinson, Peter M. Voorhees, Kristen Cassetta, Shanice Borden, Shebli Atrash, Manisha Bhutani, Cindy Varga, Mauricio Pineda-Roman, Reed Friend, Barry A. Paul
Publikováno v:
Life, Vol 14, Iss 3, p 384 (2024)
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein, exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which increases nuclear retention of tumor suppressor proteins (TSPs), i
Externí odkaz:
https://doaj.org/article/bb9f798d753b484da7597fbdf139c831
Autor:
Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina
Publikováno v:
Haematologica, Vol 109, Iss 5 (2023)
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-
Externí odkaz:
https://doaj.org/article/75a53724d8354ceda7fc08c876125b9e
Autor:
Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was def
Externí odkaz:
https://doaj.org/article/e20fe1cc56fe454eae49245689ffabf6
Autor:
Shebli Atrash, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 3, Pp 1-11 (2022)
Abstract A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes
Externí odkaz:
https://doaj.org/article/9aa1eb73d99e4fc98d10477ab43f31d5
Autor:
Al‐Ola Abdallah, Ghulam Rehman Mohyuddin, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Zahra Mahmoudjafari, Joseph McGuirk, Siddhartha Ganguly, Shebli Atrash
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 757-764 (2021)
Abstract Extramedullary disease (EMD) is an aggressive form of multiple myeloma (MM). Confirming the presence of plasma cells outside the bone marrow makes the diagnosis of EMD. There is no clear consensus on the management of EMD in MM, and this ent
Externí odkaz:
https://doaj.org/article/9b6ae2a2d7dc462bb14a482feb0aa1d7
Autor:
Shebli ATRASH, Philippe THOMPSON-LEDUC, Ming-Hui TAI, Shuchita KAILA, Kathleen GRAY, Isabelle GHELERTER, Marie-Hélène LAFEUILLE, Patrick LEFEBVRE, Adriana ROSSI
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is
Externí odkaz:
https://doaj.org/article/713cdab20a1640d499af42c645824563
Autor:
David Foureau, Manisha Bhutani, Fei Guo, Katherine Rigby, Marina Leonidas, Elise Tjaden, Andee Fox, Shebli Atrash, Barry Paul, Peter M. Voorhees, Saad Z. Usmani
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 6933-6936 (2021)
Externí odkaz:
https://doaj.org/article/9995971983e1459cb5f33ecbf93952fc